Reading view
From Model Choice to Model Belief: Establishing a New Measure for LLM-Based Research
PathFound: An Agentic Multimodal Model Activating Evidence-seeking Pathological Diagnosis
Immunotherapy for virus-related hepatocellular carcinoma: recent progress and future directions
Ann Med. 2026 Dec;58(1):2607229. doi: 10.1080/07853890.2025.2607229. Epub 2025 Dec 26.
ABSTRACT
BACKGROUND: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remaining the predominant etiological factors. Chronic viral infection not only drives carcinogenesis but also reshapes the hepatic immune microenvironment, profoundly influencing the efficacy and safety of immunotherapy.
RECENT ADVANCES: Immune checkpoint inhibitors (ICIs) have revolutionized systemic therapy for advanced HCC, with agents targeting PD-1/PD-L1 demonstrating clinical benefit. Combination strategies - such as ICIs with anti-angiogenic therapies, multikinase inhibitors, or locoregional treatments - have shown synergistic efficacy and are now standard of care in certain settings. For virus-related HCC, antiviral therapy improves immune responsiveness and reduces risks such as HBV reactivation, underscoring the need for integrated management.
FUTURE PERSPECTIVES: Emerging therapeutic approaches include next-generation immune checkpoints (e.g. TIM-3, LAG-3, TIGIT), bispecific antibodies, cellular therapies (CAR-T, TCR-T, TILs), and tumor vaccines targeting viral or tumor-associated antigens. Advances in biomarker discovery, including circulating tumor DNA, immune signatures, and microbiome modulation, are expected to guide personalized treatment. Integration of multi-omics and clinical data will further refine patient selection and optimize treatment sequencing.
CONCLUSION: Immunotherapy offers new hope for patients with virus-related HCC, but challenges remain in response heterogeneity, resistance, and toxicity. Individualized strategies that combine immunotherapy with effective antiviral management and biomarker-|guided patient selection are essential. Continued translational and clinical research into virus-immune-tumor interactions will enable safer, more effective, and more durable treatment outcomes, ultimately transforming HCC into a more manageable disease.
PMID:41454610 | PMC:PMC12777805 | DOI:10.1080/07853890.2025.2607229
Developing and Evaluating Guidelines to Prevent Overdependence on Digital Therapeutics in Children and Adolescents: Randomized Controlled Trial
A novel evaluation benchmark for medical LLMs illuminating safety and effectiveness in clinical domains
npj Digital Medicine, Published online: 26 December 2025; doi:10.1038/s41746-025-02277-8
A novel evaluation benchmark for medical LLMs illuminating safety and effectiveness in clinical domainsDistributional AGI Safety
Data-Chain Backdoor: Do You Trust Diffusion Models as Generative Data Supplier?
AI4EOSC: a Federated Cloud Platform for Artificial Intelligence in Scientific Research
Toward Closed-loop Molecular Discovery via Language Model, Property Alignment and Strategic Search
Voice-Interactive Surgical Agent for Multimodal Patient Data Control
First, do NOHARM: towards clinically safe large language models
ValuePilot: A Two-Phase Framework for Value-Driven Decision-Making
A data-physics hybrid generative model for patient-specific post-stroke motor rehabilitation using wearable sensor data
COMMA: A Communicative Multimodal Multi-Agent Benchmark
From Clicks to Preference: A Multi-stage Alignment Framework for Generative Query Suggestion in Conversational System
Grounding Large Language Models in Clinical Evidence: A Retrieval-Augmented Generation System for Querying UK NICE Clinical Guidelines
H&E-based MSI/MMR testing with AI in colorectal cancer: a multi-centred blinded evaluation
npj Digital Medicine, Published online: 15 December 2025; doi:10.1038/s41746-025-02218-5
H&E-based MSI/MMR testing with AI in colorectal cancer: a multi-centred blinded evaluation